INTRODUCTION
mutant SEB proteins has also been attempted. Toxoid-based formalin-inactivated SEB vaccination was 76 not reproducibly protective (36). More recently, engineered, non-toxic mutant forms of SEB have been 77 investigated for their ability to induce protective immune responses (3, 33, 37). In particular, a triple 78 mutant carrying L45R, Y89A, and Y94A modifications was expressed as a recombinant protein in E. coli
79
(E. coli-mSEB) (37). This non-toxic mutant was subsequently shown to induce immunity in mice (33, 37) 80 and nonhuman primates (3, 37), and to protect these animals from death when challenged with wild-type 81 SEB. Phase I clinical trials for this potential vaccine candidate, designated STEBVax, are pending.
82
In an effort to develop a sustainable platform for manufacturing protein-based vaccine candidates,
83
we expressed the same triple mutant (37) carrying L45R, Y89A, and Y94A modifications in transgenic 84 soybean seeds. We found that this soybean-derived, non-toxic mutant of SEB (soy-mSEB) could be 85 stably expressed, stored in seeds for extended periods of time at room temperature, and purified from 86 contaminating soy proteins in rapid fashion.
87
To test the efficacy of vaccination with soy-mSEB, we developed a sub-lethal challenge model in 88 pigs. Weaponized SEB is an incapacitating agent, yet animal models (3, 33, 37) have routinely relied on 89 death as an endpoint following exposure to extremely high doses of toxin. Since native SEB functions as 90 a superantigen in pigs, it was possible to define an SEB dose which induced incapacitation, but not 91 death, as a more sensitive endpoint for evaluating soy-mSEB and E. coli-mSEB as candidate vaccines.
92
Following vaccination of pigs with these immunogens, high anti-SEB antibody titers and a reduction in the 114 to feed and water ad libitum.
115

Expression of mutant SEB (L45R, Y89A, Y94A) in transgenic soybean seeds (soy-mSEB).
116
A plant codon-optimized mutant SEB sequence was used to create binary vector using methods similar 117 to those previously described (11, 13, 26, 28) . This non-toxic form of SEB encoded a triple mutation
118
(L45R/Y89A/Y94A), which has been previously shown to have no toxicity in a variety of assay systems
119
(22, 32, 37, 39).
120
Agrobacterium-mediated soybean transformations were performed as described previously (11, 121 13, 26, 28). Putative transgenic events were taken to maturity and T 1 seeds were collected. Genomic
122
DNA was prepared from individual cot chips and used in PCR to screen for the presence of the 123 transgene. Seed proteins were also extracted from individual cot chips and used in western analyses 124 and ELISAs to screen and quantify transgenic mSEB. Based on results from these assays, select seeds 125 were germinated and propagated over several generations.
126
Storage of transgenic seeds expressing soy-mSEB. Transgenic seeds (20 seeds per lot) were 127 stored in brown envelopes under ambient laboratory conditions (35% relative humidity, 21-24ºC) from Transgenic soybean seeds containing mSEB were ground to a fine powder in a generic coffee grinder.
131
Seed protein was extracted by sonication in 50 mM Tris-HCl (pH 7.8) at a ratio of ~20 ml buffer per gram 132 dry seed powder. The sonicated protein mixture was clarified by centrifugation, and endogenous acidic 133 proteins were precipitated by lowering the pH to 4.5. Insoluble proteins were removed by centrifugation 134 and the pH of the soluble extract was raised to 8.0 prior to passage over DEAE cellulose. The DEAE 135 flow through fraction was collected, dialyzed against 50 mM MES (pH 6.0) and then passed over CM 136 cellulose. Proteins bound to the CM resin were eluted using a 0-250 mM NaCl step gradient. Western 137 analysis was used to monitor soy-mSEB in protein fractions throughout the purification procedure.
138
Purified mSEB was quantified using the Bradford reagent (with BSA as a standard) and purity was 139 determined by Coomassie-blue staining of SDS-PAGE gels.
140
Expression and purification of mutant SEB (L45R, Y89A, Y94A) from E. coli (E. coli-mSEB).
141
The soybean codon-optimized mSEB open reading frame was cloned into a pET expression vector and 142 transformed into E. coli. Following selection and molecular verification, bacterial cultures containing the 143 expression plasmid were grown to stationary phase in terrific broth at 37ºC for 16 hours. IPTG was not 144 needed to induce expression of mSEB. Cells were harvested by centrifugation and the cell paste was 145 resuspended in 50 mM phosphate buffer (pH 6.3) and sonicated on ice. Soluble and insoluble protein 146 fractions were separated by centrifugation and nickel resin was used to bind protein from the soluble 147 fraction. Recombinant protein was eluted with 50 mM phosphate buffer containing 400 mM imizazole.
148
Western analysis was used to monitor mSEB throughout the purification procedure. Eluted E. coli mSEB 149 was quantified using the Bradford reagent (with BSA as a standard) and purity was determined by
150
Coomassie-blue staining of SDS-PAGE gels.
151
Protease digestion. Protease (cat# P-8811, Sigma-Aldrich, St Louis, MO, USA) was added to 152 four tubes containing 10µg of recombinant mSEB at increasing concentrations (0.0003, 0.0006, 0.0012, 153 0.0025 Units) and incubated at 37°C for 10 minutes. Samples were removed and mixed with SDS-PAGE 154 loading buffer, boiled for 10 minutes, and subjected to SDS-PAGE and western blot analysis.
155
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Western blot analysis. Proteins were separated by SDS-PAGE and transferred in CAPS buffer
156
(pH 11) to Immmobilon-P membrane (Millipore, Bedford, MA, USA). Membranes were blocked overnight 157 at 4°C with 5% nonfat milk in PBS and incubated with rabbit anti-SEB serum (1:5000) for 1 h at 23°C 158 and washed three times (10 min each) with PBS containing 0.05% Tween. Membranes were then 159 incubated with goat anti-rabbit HRP-conjugated IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
160
for 30 min at 23°C and washed as described above. Detection was carried out using the SuperSignal
161
West Pico substrate kit (Thermo Scientific, Rockford, IL, USA).
162
Induction of cytokine production by native SEB and soy-mSEB. To assess the ability of 
170
Varying concentrations of native SEB (10 -1.0 ug/ml, Sigma-Aldrich), or purified soy-mSEB (10 - 
216
Statistical analysis. For analysis of growth performance, data were analyzed using the MIXED 217 procedure of the Statistical Analysis System (SAS 9.1, Cary, NC). Significance was declared when P < 
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To demonstrate the stability of soy-mSEB, transgenic seeds were harvested from plants and 235 stored at ambient temperature for as long as three years. Western blot analyses were performed using
236
antibodies against SEB to demonstrate the presence of intact soy-mSEB. Figure 1D (left panel) shows a
237
representative Western blot of soy-mSEB at the predicted size of 28kDa in seeds that were stored for 3 238 years at ambient temperature. In our routine seed screening, we saw no evidence of detectable, smaller 239 fragments which would be indicative of mSEB degradation regardless of the storage time. Figure 1D 240 (right panel) shows that when treated with trypsin, degraded mSEB fragments could be detected using (Fig. 5A ), IL-6 (Fig. 5B) , IL-8 (Fig. 5C ), IL-12p40 (Fig. 5D) , IFN-gamma 287 (Fig. 5E) , and TNF-alpha (Fig. 5F ) responses were followed in each pig immunized with soy-mSEB, or E. (Fig. 5) .
291
Overall, pigs immunized with soy-mSEB showed significantly reduced cytokine responses 292 following native SEB challenge when compared to controls (Fig. 5) . The most dramatic reductions in the 293 cytokine response included IL-6 (Fig. 5B) , IL-8 (Fig. 5C), IFN-gamma (Fig. 5E) , and TNF-alpha (Fig. 5F ).
294
More modest overall decreases in IL-1 beta (Fig. 5A ) and IL-12p40 (Fig. 5D) were also observed.
295
Similar results were observed in pigs immunized with E. coli-mSEB (Fig. 5) . In total, the 296 reductions in toxin-induced cytokine production in these vaccinated pigs mirrored that observed in pigs 297 immunized with soy-mSEB. We concluded from these results that immunization with either vaccine 298 candidate induced immunity that was substantially equivalent as assayed by the ability to reduce a native 
316
Therefore the goal of therapeutic interventions targeting SEB toxicity should focus on eliminating 317 the ability of this agent to incapacitate. Likely, this will be a more difficult milestone to achieve than 318 merely reducing any modest mortality that might have occurred following weaponized or bioterrorism-319 delivered SEB. This rationale directed our efforts to develop an incapacitating pig model using sub-lethal 320 toxin exposure. Such a model more closely mimics what would occur within populations, and provides 321 much more sensitive efficacy endpoints (Fig. 5 ) than models which rely on death following exposure to 322 extreme dosages of native toxin (2-3, 17, 37).
323
While it is generally accepted that a cytokine cascade rapidly initiates clinical symptomology (Fig. 2) , it is logical to assume that this animal's response could mirror the human 328 condition. If this assumption is accurate, then the data reported here represent some of the first to 329 quantify the kinetics and magnitude of an acute cytokine response following an incapacitating, sub-lethal 330 dose of SEB that might be relevant to humans (Fig. 5) .
331
Unfortunately, other animal models provide little insight when attempting to understand the SEB-332 induced cytokine cascade in humans. It is not surprising that mouse models of SEB toxicity which 333 require LPS potentiation (3, 32-33, 37) do not induce cytokine responses (3, 32-33, 37) that are similar in 334 kinetics or magnitude to those observed here (Fig. 5) . SEB does not function as a superantigen in 335 normal mice (3, 32-33, 37), and the potentiator, LPS, can influence the cytokine response by itself.
336
Attempts to genetically manipulate mice by expressing HLA class II increase responsiveness of these 337 animals to SEB (10, 30). However the cytokine responses reported for these animals (10, 30) do not 338 mimic the cytokine responses observed here (Fig. 5) . It seems likely to assume that the cytokine 339 response in pigs, for which SEB functions as a superantigen (Fig. 2) , would be more representative of the 
345
SEB induced lethality models have also been developed in pigs and primates. An SEB dose of 346 150 ug/kg was lethal to 100% of piglets (2, 39), suggesting that this dose represented more than 5 times 347 the LD 50 . Analyses of serum cytokine responses following this lethal injection were quite modest (2) 348 compared to those observed here (Fig. 5) . For example, the IL-6 and IL-8 responses following lethal 349 injection (150 ug/kg) did not exceed 15 and 35 pg/ml, respectively (2). By comparison, we observed IL-6
350
and IL-8 serum levels of approximately 22,000 and 10,000 pg/ml at peak times following injection with 351 sub-lethal SEB (25 ug/ml), respectively. Whether these differences were due to SEB dosages, the age of 
363
of SEB (Fig. 5) . Pigs clearly recognize this toxin as a superantigen (Fig. 2) , and the resulting cytokine 364 response is rapid and dramatic (Fig. 5) . As toxin is cleared and pigs begin to recover, the cytokine 365 response abates. Additional studies will be required to define which particular cytokines make the 366 greatest contribution to the pathophysiology associated with exposure to sub-lethal doses of SEB. implemented. Active immunization against modified or mutant SEB proteins seems promising; however it 371 is difficult to assess the efficacy of such efforts. One SEB mutant (L45R, Y89A, and Y94A) has shown 372 the promise of being non-toxic (3, 14, 37), as well as stimulating antibodies which neutralize native toxin 373 (Fig. 4, (3, 14, 37) ). Vaccination studies using formulations with alum-based adjuvants demonstrated its 
378
protection when using such mutant SEB vaccine formulations. While high titers against native SEB were 379 achieved using soy-mSEB or E. coli-mSEB (Fig. 3B) , and toxin-induced cytokine responses were 380 reduced (Fig. 5) , immunized pigs still experienced some level of incapacitation. These symptoms 381 included emesis, prostration, and/or lethargy, and at least one of these symptoms were observed in each 
395
While questions still remain regarding the efficacy of mSEB vaccinations using alum adjuvants, 
406
The preclinical biodefense vaccine candidate selected for this study was triple mutant of SEB (3, 
413
Stability of E. coli-derived SEB was stated to be 1 year when stored at -70 0 C (6). This result
414
implies that every year, this expensive, laborious production and purification scheme must be repeated if
415
there is to be a ready available stock of vaccine for use in response to a bioterrorism threat that may or 416 may not occur. Alternatively, soy powder made from transgenic seeds expressing soy-mSEB was found 417 to be stable over many years at ambient storage temperatures (Fig. 1D) . The implications of this finding The total soluble protein extracted from the E. coli cell pellet was taken from a previous report (6).
448
Theoretically, 320 grams of protein can be extracted from 800 grams of soy powder since approximately
449
40% of the total mass is protein (4). This number assumes minimal loss of protein during the extraction 450 procedure.
452
5 The recoverable yield of E. coli-derived-mSEB total was taken from a previous report (6). Theoretically,
453
for transgenic seeds expressing soy-mSEB at 4%, 320 grams of total protein contains approximately 12.8 454 grams of soy-mSEB (4). This number does not account for any losses during the purification procedures. 
471
Levels of interferon gamma that were below the 50 pg/ml detection limit for this ELISA were designated 
